Summary
Somatostatin levels were measured in cerebrospinal fluid of patients with Alzheimer's disease, multi-infarct dementia and normal pressure hydrocephalus and compared with levels from a normal control group. All pathological groups showed a statistically significant decrease of somatostatin with respect to the control group, but no significant differences were found amongst them. A negative correlation was found between the Mini Mental State Test and the somatostatin levels in Alzheimer's disease patients but not in the other groups. Our results confirm that the lower levels of somatostatin in cerebrospinal fluid are not specific to Alzheimer's disease and indicate that the decrease found in all the groups is probably the result of neuronal destruction or damage in the diseases examined.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Alom J, Galard R, Catalan R, Castellanos JM, Schwartz S, Tolosa E (1990) CSF neuropeptide Y in Alzheimer's disease. Eur Neurol (in press)
Atack JR, Beal MF, May C, Kaye JA, Mazurek MF, Kay AD, Rapoport SI (1988) Concentrations in aging and in dementia of the Alzheimer type with and without extrapyramidal signs. Arch Neurol 45:269–273
Beal MF, Martin JB (1986) Neuropeptides in neurological disease. Ann Neurol 20:547–565
Beal MF, Growdon JH, Mazurek MF, Martin JB (1986) CSF somatostatin-like immunoreactivity in dementia. Neurology 36:294–297
Blessed G, Tomilson BE, Roth M (1968) The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 114:797–811
Catalan R, Galard R, Schwartz S, Molins A, Sahuquillo J, Castellanos JM (1989) C18 cartridge extraction method to measure calcitonin in human cerebrospinal fluid. Clin Chim Acta 182:309–312
Cramer H, Kohler J, Ocpen G, Schomberg G, Schoter E (1981) Huntington's chorea: measurements of somatostatin, substance P and cyclic nucleotides in the cerebrospinal fluid. J Neurol 228:183–187
Cramer H, Schaudt D, Rissler K, Strubel D, Warter JM, Kuntzmann F (1985) Somatostatin-like immunoreactivity and substance P-like immunoreactivity in the CSF of patients with senile dementia of Alzheimer type, multi-infarct syndrome and communicating hydrocephalus. J Neurol 232:346–351
Davis KL, Davidson M, Yang RK, Davis BM, Sievers LJ, Mohs C, Ryan T, Coccaro E, Bierer L, Targum SD (1988) CSF somatostatin in Alzheimer's disease, depressed patients and control subjects. Biol Psychiatry 24:710–712
Dupont E, Christensen SE, Hansen AP, Olivarius BF, Orskov H (1982) Low cerebrospinal fluid somatostatin in Parkinson's disease: an irreversible abnormality. Neurology 32:312–314
Fisher CM (1977) The clinical picture in occult hydrocephalus. Clin Neurosurg 24:270–284
Folstein MF, Folstein SE, McHugh PR (1975) Mini Mental State. A practical method for grading the cognitive state of patients for the clinician. J Psychiatry Res 12:189–198
Gomez S, Davous P, Rondot P, Faivre-Bauman A, Valade D, Puymirat J (1986) Somatostatin-like immunoreactivity and acetylcholinesterase activities in cerebrospinal fluid of patients with Alzheimer disease and senile dementia of Alzheimer type. Psychoneuroendocrinology 11:69–73
Hachinski VC, Iliff LD, Zilhka E, et al (1975) Cerebral blood flow in dementia. Arch Neurol 32:632–637
Hrisch B (1978) Hypothalamic and non-hypothalamic distribution of neurotensin and somatostatin-immunoreactive elements in the rat brain. Cell Tissue Res 195:499–513
Klosovsky BN (1968) Hydrocephalus. In: Minckler J (ed) Pathology of the nervous system. McGraw-Hill, New York, pp 456–462
Kohler J, Schroter E, Cramer H (1982) Somatostatin-like immunoreactivity in the CSF of neurological patients. Arch Psychiatr Nervenkr 231:503–508
Krieger DT (1983) Brain peptides: what, where and why? Science 222:975–985
McKlann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer's disease. Neurology 34:939–944
Rubinow DR, Gold PW, Post RM, Ballenger JC, Cowdry R, Ballinger J, Reichlin S (1983) CSF somatostatin in affective illness. Arch Gen Psychiatry 40:409–412
Rubinow DR, Davis CL, Post RM (1988) Somatostatin in neuropsychiatric disorders. Prog Neuropsychopharmacol Biol Psychiatry 12:137–155
Serby M, Richardson SB, Twente S, Siekierski J, Corwin J, Rotrosen J (1984) Somatostatin in Alzheimer's disease. Neurobiology 5:187–189
Snyder DT (1980) Brain peptides as neurotransmitters. Science 209:976–983
Sioninen HS, Jolkonen JY, Rainikainen KJ, Halonen TO, Riekkinen PJ (1984) Reduced cholesterinase activity and somatostatin-like immunoreactivity in the CSF of patients with demetia of Alzheimer type. J Neurol Sci 63:167–172
Sorensen KV, Christensen SE, Dupont E, Hansen AP, Pedersen E, Orskov H (1980) Low somatostatin content in cerebrospinal fluid in multiple sclerosis. Acta Neurol Scand 61:186–191
Sunderland T, Rubinow Dr, Tariot PN, Cohen RM, Newhouse PA, Mellow AM, Mueller EA, Murphy DL (1987) CSF somatostatin in patients with Alzheimer's disease, older depressed patients and age matched control subjects. Am J Psychiatry 144:1313–1316
Urakami K, Adachi Y, Awaki E, Takahashi K (1989) Characterization of the course of senile dementia of the Alzheimer type using cerebrospinal fluid levels of acetylcholinesterase and somatostatin. Acta Neurol Scand 80:232–237
Wood PL, Etienne P, Lal S, Gauthier S, Cajal S, Nair NPH (1982) Reduced lumbar CSF somatostatin levels in Alzheimer's disease. Life Sci 31:2073–2079
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Molins, A., Catalán, R., Sahuquillo, J. et al. Somatostatin cerebrospinal fluid levels in dementia. J Neurol 238, 168–170 (1991). https://doi.org/10.1007/BF00319684
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00319684